To summarize highlights from the 10th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), emphasizing the significance of recent advancements in understanding and managing hidradenitis suppurativa (HS).
Key Findings:
HS shows a more intense upregulation of Th17/IL-17 pathways compared to psoriasis, suggesting IL-17 targeting may be more effective, which could lead to improved treatment outcomes.
Dermal tunnels in HS are unique lesions that sustain chronic inflammation and are linked to specific molecular markers, indicating potential targets for future therapies.
Pediatric HS has a similar comorbidity burden to adult HS, highlighting the need for more focused research in this area to improve management strategies.
Interpretation:
The findings indicate a need for disease-specific immunotherapy targets and further research into the unique pathophysiology of HS, particularly regarding dermal tunnels and pediatric cases, which could significantly influence treatment approaches.
Limitations:
The symposium did not present new studies involving human participants or animals, limiting the applicability of the findings.
Some studies discussed had limitations such as lack of control matching in observational research, which may affect the reliability of the conclusions drawn.
Conclusion:
The SHSA 2025 highlighted significant advancements in HS research and emphasized the importance of targeted therapies and understanding unique disease mechanisms, underscoring the need for collaborative efforts in future research.
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
